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Abstract: Induction of antiviral innate immune responses depends on a family of innate immune receptors, the Toll-like 
receptors (TLR). TLR mediate the antiviral immune responses by recognizing virus infection, activating signaling path-
ways and inducing the production of antiviral cytokines and chemokines. ssRNA and dsRNA viruses can be recognized 
by TLR7/8 and TLR3, respectively. TLR receptors are also involved in the recognition of viruses containing genomes rich 
in CpG DNA motifs as well as envelope glycoproteins. Cytoplasmic recognition of dsRNA by RNA helicases such as 
RIG-I and MDA5 provides another means of recognizing viral nucleic acid. In order to counteract the innate host immune 
system viruses evolved mechanisms that block recognition and signaling through pattern recognition receptors, such as 
TLRs and RNA helicases. Recently, TLR agonists represent a promising approach for the treatment of infectious diseases. 
This review will focus on the current knowledge of TLR-mediated immune responses to several viral infections. 
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INTRODUCTION 
  Toll-like receptors (TLRs) are crucial in the innate im-
mune response to pathogens, in that they recognize and re-
spond to pathogen associated molecular patterns (PAMPs), 
which lead to activation of intracellular signaling pathways 
and altered gene expression. The host innate immune system 
detects microorganisms and responds to their stimuli mainly 
through recognition of TLRs [1]. Members of the family of 
TLRs have emerged as key sensors of innate immunity to 
viruses recognizing their components such as nucleic acids 
and envelope glycoproteins. Engagement of TLRs leads to a 
series of signaling events resulting in the production of type I 
interferons, inflammatory cytokines and chemokines, and 
induction of immune responses necessary to eliminate the 
pathogens [2]. Sensing through TLRs induces maturation of 
dendritic cells (DCs), thereby initiating adaptive immune 
responses [3]. Cells also express cytoplasmic RNA helicases 
that function as an alternative class of pattern-recognition 
receptors through recognition of double-stranded RNA 
(dsRNA) produced during virus replication. These two 
classes of pattern-recognition receptor molecules are ex-
pressed in different intracellular compartments and induce 
type I interferon responses via distinct signaling pathways 
[1,2,4]. TLRs patrol the extracellular and endosomal com-
partments, while the RNA helicases retinoic acid-inducible 
gene I (RIG-I) and melanoma differentiation-associated gene 
5 (MDA5) survey the cytoplasm for the presence of viral 
dsRNAs. RNA helicases and the TLR system exert antiviral 
responses in a tissue- and cell type-specific manner [5]. 
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  Viruses are characterized by the complexity of their ge-
nomes and they are classified according to the underlying 
mechanisms of replication (Baltimore classification). The 
nucleic acid in viral genomes can be either DNA or RNA, 
positive or negative in polarity, single-stranded or double-
stranded, and one continuous (sometimes circular) molecule 
or a molecule with segmented configuration. Four TLR 
members seem to play a critical role in recognition of viral 
nucleic acids [6]: TLR3 recognizes dsRNA (dsRNA consti-
tutes the genome of one class of viruses, but is also gener-
ated during the life cycle of many viruses), TLR7 and 8 rec-
ognize single-stranded RNA (ssRNA) and TLR9 responds to 
dsDNA viruses recognizing non-methylated viral CpG-
containing DNA. Although the majority of TLRs sense 
pathogen components on the cell surface, TLR3, TLR7, 
TLR8 and TLR9 sense nucleic acids in endosomal compart-
ments. Other TLRs are also involved in viral recognition; 
TLR2 and TLR4 were shown to detect viral components 
such as envelope glycoproteins [6-9]. 
  Members of the TLR family detect viruses that enter the 
endosome through endocytosis. This pathway induces pro-
duction of interferons through several signaling proteins that 
ultimately lead to the activation of the transcription factors 
NF-kB, IRF3 and IRF7 [1,10,11] (Fig. 1). Specifically, upon 
ligand binding the receptor complex recruits, via  its cyto-
plasmic Toll/IL/1 receptor (TIR) domain, the TIR-containing 
cytosolic adapter protein MyD88, the TIRAP/Mal (appears 
to function downstream TLR2 and TLR4) and the Toll-IL1 
receptor domain-containing adaptor inducing IFN-beta 
(TRIF, also known as TICAM-1) appears to function down-
stream of TLR3 and possibly TLR4. The adapter MyD88, in 
turn, recruits the interleukin 1R-associated kinase (IRAK) 
complex. IRAK are active kinases dissociating from the re-
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ing with TNF receptor-associated factor 6 (TRAF6). TRAF6 
then activates at least two distinct signaling pathways lead-
ing to the activation of NF-B and mitogen activated protein 
kinases (MAPKs), the extracellular signal-regulated kinase 
(ERK), p38 and the c-Jun N-terminal kinase (JNK) [12]. 
TRIF appears to be responsible for the induction f IFN-
alpha and IFN-beta gene expression by TLR3 and TLR4 
through a MyD88-independent pathway. Two kinases, TBK1 
and IKK, were shown to function downstream of TRIF and 
upstream of IRF3 (interferon regulatory factor 3), a tran-
scription factor responsible for the induction of IFN genes 
(Fig. 1). 
  Cytoplasmic recognition of dsRNA by RNA helicases 
such as RIG-I and MDA5 provides another means of recog-
nizing viral nucleic acid [4]. Signaling events downstream of 
RIG helicases reveal the presence of an adaptor molecule 
that contains a caspase recruitment domain (CARD). RIG-I 
activates NF-B and IRFs through the recently identified 
adaptor protein MAVS/VISA/Cardif/IPS-1 that resides in the 
mitochondrial membrane [13]. This adaptor molecule is the 
sole adaptor in both RIG-I and MDA-5 signaling able to me-
diate effective responses against a variety of RNA viruses 
[14].  
  Type I interferons, IFN-alpha and IFN-beta, are potent 
antiviral cytokines and modulators of the adaptive immune 
system. They are induced upon viral infection or by dsRNA 
and lead to the production of a broad range of antiviral pro-
teins and cytokines. Viruses, in turn, have evolved multiple 
strategies to counteract the interferon system which would 
otherwise stop virus growth early in infection [15]. Despite 
the fact that activation via TLR molecules can lead to antivi-
ral innate immune responses, in some cases viruses use these 
responses to ameliorate infection [16] and to counter-
act/escape the host immune system [17-19]. 
VIRUSES AND TLRs 
Viruses with dsRNA and TLR-3 
  Toll-like receptor 3 (TLR3) recognizes dsRNA, a univer-
sal viral molecular pattern, and thus, is involved in antiviral 
host immune responses [20]. A synthetic ligand, poly(I:C), 
can also mediate responses through TLR3. TLR3 has been 
identified to respond to dsRNA by specifically recognizing 
purified genomic dsRNA from Lang reovirus and poly(I:C) 
[20], resulting in the induction of IFN-beta, IL-12, IL-6 and 
TNF-alpha. However, studies with TLR3-deficient mice 
provide evidence suggesting that TLR3 does not play a criti-
cal role in the host antiviral immune responses to reovirus 
(dsRNA virus) because susceptibility to infection and gen-
eration of T cell immune responses to this virus were equiva-
lent in TLR-deficient and –sufficient mice [20,21].  
  The role of TLR3 was also investigated in rhinoviral in-
fections [22]. Rhinoviruses are the major cause of the com-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). TLR signal transduction pathway. TLR2 can form a homodimer or a heterodimer with TLR1 and TLR6. TLR3, TLR7, TLR8 and 
TLR9 localize in endosomal compartments. LPS activates TLR4. Each TLR mediates distinctive responses in association with TIR domain-
containing adapters (MyD88, TIRAP/MAL, TRIF and TRAM). IRAK and TRAF6 activate NF-B and induce inflammatory cytokine secre-
tion activating the IFN pathway.  Toll-Like Receptors and Viruses  The Open Microbiology Journal, 2008, Volume 2    51 
mon cold and their replication induces expression of TLR3 
mRNA and surface protein expression. TLR3 mediates anti-
viral activity in human bronchial epithelial cells infected 
with rhinovirus. Blocking of TLR3 during infection impairs 
the antiviral response, resulting in increased rhinovirus repli-
cation [22]. 
  TLR3 plays an important role in the pathogenesis of 
West Nile virus, a ssRNA flavivirus. This virus replicates 
through a dsRNA intermediate and causes human disease of 
variable severity. Infection with West Nile virus leads to a 
TLR3-dependent inflammatory response that mediates entry 
and penetration of the virus into the brain causing lethal en-
cephalitis [23]. Viral replication in peripheral tissues triggers 
inflammation leading to secretion of cytokines such as inter-
ferons, IL-6 and TNF-alpha. Signaling through TNFR1 par-
ticipates in the blood-brain barrier breakdown upon TLR3 
stimulation or viral infection with West Nile virus. Thus, 
TLR3-dependent induction of TNF-alpha facilitates penetra-
tion of West Nile virus across the blood-brain barrier and 
induces neuronal injury [23,24]. 
  Another interesting feature of TLR3 is that it promotes 
cross-priming to virus-infected cells. It has been proposed 
that TLR3 may have evolved to permit cross-priming of cy-
totoxic T cells against viruses that do not directly infect den-
dritic cells [25]. 
  Evidence to date shows that TLR3 is not universally re-
quired for the generation of effective antiviral responses 
[21,26], proposing a potential role for other pattern recogni-
tion receptors. In this regard, RNA helicases represent an 
alternative major cellular sensor for several viral infections 
associated with dsRNA.  
Single-Stranded RNA Viruses and TLR7/TLR8, Other 
TLRs and RNA Helicases 
  TLR7 and TLR8 are usually present in the endosomal 
compartments and sense ssRNA of viruses [27-29] present in 
the extracellular milieu and engulfed them through the proc-
ess of endocytosis. Through this exogenous pathway, RNA 
within internalized virions is detected by TLR7 in en-
dosomes after digestion of the viral envelope and capsid pro-
teins by host cell enzymes. Recently, another pathway had 
been shown to exist. Plasmacytoid dendritic cells (pDCs) 
recognize some viruses such as vesicular stomatitis virus 
(VSV) or Sendai virus through an endogenous pathway, 
where autophagy performs an analogous function to endocy-
tosis, transferring viral RNA from the cytoplasm to the en-
dosomal compartments containing TLR7 [30,31]. 
  Regardless the route of ssRNA virion internalization, 
whether by fusion with the plasma membrane (as for VSV-
RSV-F or Sendai virus), or by fusion with the endosomal 
membrane (as for VSV or influenza virus), sensing occurs 
within the endosome because acidification of the endosomal 
vacuole is required for an antiviral response [32]. 
  In epithelial cells infected with RSV (a negative ssRNA 
virus), TLR3 mediates inflammatory cytokine and 
chemokine production [33]. Mice infected with influenza 
virus constitutively up-regulate TLR3. Animals deficient in 
TLR3 show reduced inflammatory mediators and lower 
number of CD8-positive T lymphocytes in the bronchoalveo-
lar airspace [34]. It is relevant to note that IFN-alpha and 
F-alpha enhance the expression of TLR3, MyD88, TRIF, 
IRF7 and RIG1 in human lung A549 epithelial cells infected 
with influenza A virus [35].  
  Using TLR4-deficient mice it was evident that TLR4 is 
involved in the innate immunity to respiratory syncytial virus 
(RSV) through an interaction with the viral envelope fusion 
protein (F protein) [7,36]. Sendai virus shares many features 
with RSV including a structurally and functionally similar F 
protein. Despite these similarities, TLR4 is not involved in 
host defense against respiratory tract infection with Sendai 
virus [37]. 
  RNA helicases sense viral infections associated with ac-
cumulation of dsRNA in the cytoplasm. Both RIG-I and 
MDA5 detect dsRNA; however, MDA5 recognizes poly(I:C) 
and RIG-I detects in vitro transcribed dsRNAs [38]. RNA 
viruses are differentially recognized by these helicases: RIG-
I mediates antiviral responses to paramyxoviruses, influenza 
virus and Japanese encephalitis virus, whereas MDA5 is 
critical for host antiviral response to picornaviruses [38]. In 
another study RIG-I was essential for signaling by influenza 
viruses and human respiratory syncytial virus (RSV) 
whereas RIG-I and MDA5 were each individually dispensa-
ble for signaling triggered by reovirus and dengue virus [39]. 
  Several lines of evidence point to cell-type specificity in 
the recognition process of infecting viruses [38,40]. For ex-
ample, activation of signal transduction and induction of 
cytokine expression by the paramyxovirus Sendai is depend-
ent on virus replication and involves pattern recognition re-
ceptors in a cell-type-dependent manner: Cells that are not 
part of the immune system, such as human embryonic kidney 
cells, rely entirely on recognition of dsRNA through RIG-1 
while cells of myeloid origin, which include macrogphage-
like cell lines, utilize TLR7/8 [40]. RIG-I is essential for 
induction of type I interferons following an infection with 
ssRNA viruses in fibroblasts and conventional DCs. In con-
trast, plasmacytoid DCs (pDCs) use the TLR system rather 
than RIG-I for viral detection [38]. 
dsDNA Viruses and TLRs 
Cytomegalovirus (CMV) 
  CMV is a dsDNA virus that triggers TLR activation dur-
ing virus-cell contact and/or entry [8,41]. TLR2 recognize 
the CMV envelope glycoproteins B and H, leading to innate 
immune response by activation of NF-kB and induction of 
inflammatory cytokines [41,42]. Recently, TLR2-deficient 
mice showed elevated levels of murine CMV (MCMV) in 
the spleen and liver 4 days post-infection as compared to 
wild type (wt) C57BL/6 mice and this difference in viral 
titers was abrogated by in vivo depletion of NK cells of 
TLR2-deficient mice and C57BL/6 mice using anti-NK1.1 
antibodies [43]. Therefore, the defect in early antiviral con-
trol was associated with reduction of NK cells in the spleen 
and liver 4 days post-infection. TLR2 was also identified as 
a receptor which triggers innate immune responses against 
MCMV [43]. 
  Reactivation of MCMV from latency induced by LPS 
appears dependent on TLR4 signaling. Specifically, mice 
receiving intraperitoneal doses of LPS had pulmonary 
reactivation of latent MCMV 3 weeks following injection 
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ing was blocked using a monoclonal antibody (MTS510) 
LPS did not reactivate MCMV [44]. 
  TLR9 mediates the recognition of MCMV as evidenced 
by experiments using a mutated form of TLR9. A missense 
mutation in the receptor domain of the Tlr9 gene (TLR9
CpG1) 
can be induced by N-ethyl-N-nitrosourea showing unrespon-
siveness to CpG-containing oligonucleotides. Mice homozy-
gous for the Tlr9
CpG1 allele are highly susceptible to an infec-
tion with MCMV showing an impaired (infection-induced) 
secretion of IFN-alpha/beta cytokines and NFB activation 
[45].  
  The TLR9-mediated activation of MyD88 and TLR3-
dependent induction of TRIF signaling are activated in vivo 
upon inoculation of MCMV leading to type I interferon pro-
duction. Notably, neither of the pathways alone - in the ab-
sence of the other - offers complete protection against an 
infection with MCMV, but rather act in an additive or code-
pendent manner [45]. 
  Following an exposure to a CMV antigen, CD123-
positive pDCs and CD11c-positive myeloid DCs (mDCs) 
stimulated with TLR ligands induce autologous memory T 
cell responses specific for the CMV antigen [46]. Therefore, 
TLR ligands that specifically target DC subsets can enhance 
their ability to activate virus-specific T cells and can be used 
as adjuvants for vaccine or immune modulating therapies. 
Herpes Simplex Virus Type 1 (HSV1) 
  The dsDNA virus HSV1 is the major cause of sporadic 
lethal encephalitis and blindness in humans. Infection with 
HSV1 induces apoptotic cell death in microglial cells [47]. 
  In addition to the role of TLR2 in infections with CMV, 
TLR2 is activated in response to Varicella Zoster virus 
(VZV) [48] and it seems to play significant role in infections 
with HSV1. Lower levels of cell death are observed in 
TLR2-/- knock-out cells as compared to wt cells 24 hours 
post-infection [49].  Whereas peritoneal macrophages from 
TLR2-/- or wt mice are able to produce TNF-alpha in re-
sponse to an exposure to HSV1 (as opposed to MyD88-/- 
mice), TLR2-/- mice showed significantly lower levels of 
monocyte chemoattractant protein 1 (MCP-1) in the brain 
and reduced mortality compared to wt or TLR4-/- mice [50]. 
Moreover, an intranasal infection with HSV1 showed that 
only MyD88-/- knock-out cells were highly susceptible to 
infection; followed by viral migration to the brain, and se-
vere neuropathological signs of encephalitis and mortality by 
day 10 post-infection. Summarizing, it seems that innate 
resistance to HSV1 is mediated by MyD88 and may be acti-
vated by multiple TLRs [51]. Additionally, the Affymetrix 
microarray technology provides evidence that infection of 
the TLR3-expressing human post-mitotic neuron derivative 
cell line NT2-N with HSV1 triggers IL6 and IRF1 mRNA 
production [52]. Thus, human neurons in the absence of glia 
have an intrinsic mechanism to sense viral infection through 
TLRs [52].  
  In response to HSV1 infection, human corneal epithelial 
cell lines (HCEC, HUCL) - immortalized with telomerase - 
produce pro-inflammatory cytokines leading to infiltration in 
the cornea. The interferons produced enhance antiviral activ-
ity in the cornea by sequential activation of TLRs. Specifi-
cally, HSV1-infected HCEC cells result in a two-phase acti-
vation of NF-. Concominant with the first peak of activa-
tion a number of cytokines are expressed and during the sec-
ond phase of NF-B activation TLR7 is induced and TLR3 
down-regulated [53].  
Herpes Simplex Virus Type 2 (HSV2) 
  CpG motifs, highly present in the genomes of HSV1 and 
HSV2 as compared to other viral ds genomes, are recognized 
by TLR9 expressed on pDCs and other types of DCs [54]. 
  Local delivery of CpG oligonucleotides, acting as ago-
nists for TLR9, protects against a lethal challenge with 
HSV2 by inhibiting virus replication. HEK293 cells trans-
fected with TLR9 provide evidence that the antiviral activity 
of CpG oligonucleotides is mediated through TLR9 [55]. 
Administration of poly(I:C) protected mice showing in-
creased survival of mice even with a challenge infection with 
a 10-fold-higher HSV2 load [56]. In contrast, treatment with 
TLR4 or TLR2 ligands does not lead to a protective effect 
against a challenge infection with intravaginal HSV2 [57]. 
  Vaginal infection with tk-HSV2, a recombinant HSV2 
expressing thymidine kinase, results in a rapid recruitment of 
CD11b-positive DCs to the submucosa with their subsequent 
appearance in the lymph nodes presenting viral peptides to 
CD4-positive T cells [58]. DCs require signals from stromal 
cells - which are mediated through MyD88 - in order to 
promote generation of Th1 cells [59]. 
Adenovirus (AdV) 
  Adenovirus (AdV) is a dsDNA virus causing respiratory, 
ocular and gastrointestinal illness in humans. AdV activates 
innate immunity by its DNA through TLR–dependent and –
independent pathways in a cell-type specific fashion [60,61]. 
The recognition of AdV by pDCs is reported to be mediated 
by TLR9 and is dependent on MyD88. In contrast, recogni-
tion by non-pDCs is TLR-independent through cytosolic 
sensing of adenoviral DNA. MyD88-/- knock-out mice con-
firmed that the AdV-induced dysregulation of functionally 
related gene clusters is significantly dependent on this adap-
tor molecule which plays a significant role as an amplifier 
and regulator of adenoviral immunity in vivo [62]. 
  Recognition of AdV by TLR9 requires the adenoviral 
DNA. Efficient endosomal acidification of oligonucleotides 
that trigger TLR9 attenuates induction of IFN-alpha gene 
expression. Cell lines expressing TLR9, permissive to infec-
tion by both adenoviral serotypes utilizing the Coxsackievi-
rus-AdV Receptor (CAR) and serotypes utilizing CD46, 
show a preferential induction of TLR9-mediated events by 
AdVs utilizing CD46 for their entry [63]. Therefore, infec-
tivity alone is not sufficient for TLR9 activation but seems to 
be regulated by the specific receptor entry pathway [63]. 
Human Papillomavirus (HPV) 
  Human papillomavirus (HPV) is another dsDNA virus; 
many data strongly suggest that HPV infection is causative 
agent of cervical cancer [64]. Infection with HPV 16L1 vi-
rus-like particles (VLPs) provides immunity by activating 
DCs and a potent neutralizing IgG response, which requires 
MyD88-dependent signaling. IFN-alpha/beta as well as nu-
merous proinflammatory cytokines and chemokines are up-
regulated in response to an infection with HPV16 VLPs [65]. 
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regulate IL12, IFN-alpha and IFN-gamma in response to 
HPV16VLPs. Moreover, Th1-biased immune responses are 
impaired in mice deficient in MyD88 and IFN-alpha/beta 
receptor. These observations implicate TLRs to have a cen-
tral role in immune recognition of HPV16L1 VLPs [66]. The 
TLR7 agonist, imiquimod is already marketed for papillo-
mavirus disease [67]. 
Vaccinia Virus and TLRs 
  Innate immune recognition of vaccinia virus is mediated 
by TLR2 and MyD88 and requires TLR-independent pro-
duction of IFN-beta [68]. Both TLR-dependent and –
independent pathways are required for the activation of in-
nate and adaptive immunity to vaccinia virus in vivo [68]. 
  Vaccinia virus has been extensively used as a vaccine 
vehicle in clinical application in several studies. Previous 
studies suggested that the unique potency of vaccines based 
on vaccinia virus lies in its effective activation of the innate 
immune system [68,69]. Using microarrays it was shown 
that TLR3 is specifically induced upon infection of immature 
human monocyte-derived DCs with the attenuated poxvirus 
vector MVA [70]. 
Epstein-Barr Virus (EBV) and TLRs 
  Epstein-Barr virus (EBV) infection of primary B cells 
causes B cell activation and proliferation. TLR signaling has 
been reported to provide a third B cell activation stimulus. 
EBV up-regulates the expression of TLR7 and downregu-
lates the expression of TLR9 in naïve B cells [71]. IRF-5 is 
induced following EBV infection and B cell proliferation 
assays provide evidence that EBV modulates TLR7 signal-
ing [71]. Upon EBV infection a novel splice variant of IRF-5 
transcripts is induced acting as a dominant negative form. 
EBV therefore initially uses TLR7 signaling to enhance B 
cell proliferation and subsequently modifies the pathway to 
regulate IRF-5 activity [71]. TLR2 is also shown to play an 
important role in immune responses directed against EBV 
infection. Infectious and UV-inactivated EBV virions are 
demonstrated to lead to the activation of NF-B through 
TLR2 [9]. In addition, EBV infection of primary human 
monocytes induces the release of the chemokine monocyte 
chemotactic protein 1 (MCP-1), and small interfering RNAs 
targeting TLR2 significantly reduce the chemokine response 
to EBV [9]. 
Retroviruses and TLRs 
  The internalization of the retrovirus human immunodefi-
ciency virus type 1 (HIV-1) is mediated by interactions of 
the viral envelope with the host CD4 receptor. Viral RNA 
present in endosomal compartments and recognized by 
TLR7 [72] is the critical factor that stimulates pDCs and 
induces IFN-alpha secretion. Uridine-rich ssRNA derived 
from the HIV-1 long terminal repeat were shown to serve as 
potent activators of NK cells via  TLR7/8 [73]. HIV-1-
derived TLR ligands can contribute to the immune activation 
of NK cells and may play an important role in HIV-1-
associated immunopathogenesis as well as NK cell dysfunc-
tion observed during acute and chronic viremic HIV-1 infec-
tion [73]. Constitutive association of MyD88 with IRAK1 is 
evident in Human T cell leukaemia virus type 1(HTLV-1)-
transformed T cells; HTLV-1 Tax enhances TLR expression 
and synergistically activates NF-B through wt MyD88 [74]. 
HTLV-1 has also evolved a protein that interferes with 
TLR4 signaling. HTLV-1 p30 interacts with PU.1 and inhib-
its its DNA binding and transcription activity resulting in the 
down-regulation of TLR4 expression from the cell surface 
[75]. Expression of p30 hampers the release of pro-
inflammatory cytokines and stimulates release of anti-
inflammatory cytokines like IL-10 following stimulation of 
TLR4 in human macrophages [75]. This novel function of 
p30 may explain the reduced activation of adaptive immu-
nity in adult T-cell leukemic (ATL) patients. TLR4 also in-
duces maturation of bone marrow-derived dendritic cells and 
the up-regulation of the MMTV entry receptor (CD71) on 
these cells [76]. 
epatitis C Virus (HCV) and TLRs 
  Hepatitis C virus (HCV) is an enveloped, ssRNA virus, 
able to establish chronic infections. Pathogens are common 
in HCV-infected patients and can be recognized by TLRs, 
which are upregulated in monocytes and T cells [77,78]. 
  DCs sense virus infections via TLRs and RIG pathways 
and produce large amounts of type I IFNs and inflammatory 
cytokines [79]. Reduced expression of TLR2 on immature 
DCs from HCV-infected patients compared to the control 
group results in a lesser ability to stimulate T cell prolifera-
tion [80]. Dysfunctions of HCV-DCs have been reported by 
several other investigators. Hepatitis C virus purified from 
serum of chronically infected patients in the form of lipo-
viro-particles (LVP, triglyceride-rich lipoprotein like parti-
cles containing viral RNA and proteins) interacts with TLR4 
and activates DCs to mature and to induce through ERK and 
p38-dependent mechanisms a Th2-biased phenotype instead 
of a Th1 [81]. Th2 cells produce IL4, IL5, IL6, IL9, IL10 
and IL13 cytokines that promote B cell expansion and down-
regulate Th1 cells [79]. 
  Plasmacytoid DCs (pDCs) are known to secrete large 
amounts of IFN-alpha in response to TLR activation and are 
capable of activating naïve T cells. In HCV-infected patients 
pDCs exhibit reduced responsiveness to TLR ligation (R848 
stimulation), accompanied by reduced expression of the 
marker HLA-DR and the cytokine IFN-alpha, and impaired 
activation of naïve CD4-positive T cells [82]. In myeloid 
DCs from HCV-infected patients, the levels of TLR/RIG-I-
mediated IFN-beta or TNF-alpha induction are lower than 
those in uninfected donor despite the high expression of 
TLR2, TLR4 and RIG-1, meaning that the signal transduc-
tion is impaired in HCV-infected cells [83]. 
  There are many evidences showing that HCV compo-
nents can bind TLRs and activate their signaling pathway or 
block TLR function by interfering with intracellular inter-
mediates [78,84-88]. Several reports have shown an im-
muno-modulatory role of the HCV core protein [84]. The 
HCV core protein can associate with the cell surface receptor 
of the recognition component C1, gC1q receptor (gC1qR) on 
human monocyte-derived DCs and inhibit TLR4-induced 
IL12 production without affecting the production of other 
TLR-stimulated cytokines [84,89]. Likewise, incubation of 
mononuclear cells with the HCV core protein results in up-
regulation of TLR2 expression and suppression of TLR4 and 
TLR7 in patients and controls [78]. TLR2 may use TLR1 
and TLR6 co receptors for TLR2 activation of macrophages 
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with mouse macrophage cell lines stably expressing the 
HCV non structural proteins (NS3, NS3/4A, NS4B or 
NS5A) showed inhibition of TLR2, TLR4, TLR7 and TLR9 
signaling pathways [87]. Analysis of the effect of the entire 
or parts of the HCV open reading frame (core-NS3, NS5-
NS5B) in a liver derived cell line, HepG2, has shown that 
TLR3 expression is suppressed in the transfectants express-
ing the entire HCV open reading frame whereas it is elevated 
in the transfectant expressing core-NS3 [78]. Thus, sup-
pressed expression of TLR3 may be responsible for the per-
sistence of the virus in chronic HCV infection. 
epatitis B Virus (HBV) and TLR 
  Hepatitis B virus (HBV) is a dsDNA virus, which may 
cause acute and chronic infections. The HBV surface antigen 
(HBsAg) is most frequently used to screen for the presence 
of this viral infection. TLRs are involved in controlling HBV 
infection. Intravenous injection of transgenic mice with 
TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9 showed that 
all the ligands except TLR2 inhibited HBV replication in the 
liver non-cytopathically within 24 hours in an IFN-
alpha/beta-dependent manner [91]. Other studies reported 
that TLR2 is reduced in HBV-infected mononuclear cells 
from peripheral blood, whereas TLR4 expression was higher 
as compared to other TLRs [92]. 
  Analysing the effect of the 3’CCACCA motif of tRNA 
Ala (UCG) on the immune response of the hepatitis B antigen 
(HBsAg) in BALB/c mice showed that this motif increased 
Th1 and CTL immune responses [100]. Notably, this motif 
can be recognized by TLR3. In this regard, deletion of the 
3’CCACCA sequence of tRNA 
Ala decreased the
 recognition 
through TLR3 [93]. 
Viral Evasion of the Innate Host Immune System 
  In order to establish successful infections viruses need to 
counteract the innate host immune defences evolving 
mechanisms that block recognition and signaling through 
pattern recognition receptors, such as TLRs and RNA heli-
cases. The involvement of viral pattern recognition receptors 
and possible immune evasion mechanisms are listed in Table 
1. For example, the V proteins of paramyxoviruses bind to 
MDA5, thereby inhibiting the activation of the IFN-beta 
promoter [94]. The P protein of measles virus suppresses 
TLR signaling through up-regulation of the ubiquitin-
modifying enzyme A20 [95]. NS1 protein of influenza A 
virus antagonizes the host antiviral response by inhibiting the 
function of RIG-I. The expression of NS1 downregulates 
production of IFN-beta induced by RIG-I agonists, and ec-
topic expression of RIG-I inhibits the replication of influenza 
A virus [96]. The adenoviral E3 protein 14.7K inhibits anti-
viral immunity and inflammation by blocking the activity of 
NF-B following signaling through TLR and TNFR [97].  
  Studies on the mechanism of HCV evasion provided 
strong evidence for a virus-specific proteolysis of TRIF, an 
adaptor protein, which links TLR3 and kinases mediating 
activation of IRF3 and NF-B. The cleavage is mediated by 
the HCV protease NS3/4A, responsible for inhibition of 
poly(I:C)-activated signaling through the TLR3 pathway 
[98]. Overexpression of IKK is able to inhibit positive and 
negative replicative strands of the HCV replicon [99]. The 
RIG-1 signaling pathway is mediated by the antiviral mito-
chondrial protein MAVS/VISA/Cardif/IPS-1 which activates 
NF-B and IRFs. HCV employs the viral protease NS3/4A 
to cleave MAVS at Cys-508 resulting in the dislocation of 
the N-terminal fragment of MAVS from the mitochondria 
[88]. 
  In order to counteract the host innate immunity vaccinia 
virus encodes immunomodulatory proteins that antagonize 
important components of the host antiviral defense [100]. 
This virus encodes sequences similar to the TIR domain that 
are able to interfere with NF-B signaling. The vaccinia vi-
rus protein A52R was shown to intracellularly block the ac-
tivation of NF-B induced by multiple TLRs, including 
TLR3 [101]. This mechanism of disabling TLR signaling by 
association of A52R with IRAK2 and TRAF6 is used by 
vaccinia virus in order to suppress host immunity [101]. 
Moreover, although A52R inhibits TLR-mediated NF-B 
activation it can simultaneously activate MAP kinases and 
was shown to mediate enhancement of TLR-induced IL-10 
[102]. The viral protein A46R, having a distinct function 
from A52R, targets multiple TIR adaptor molecules, like 
MyD88 and TRIF, and contributes to virulence. A recombi-
nant vaccinia virus lacking A52R was attenuated in a murine 
intranasal model, demonstrating importance of this protein to 
the virulence [103]. Another poxvirus protein, N1L, was also 
shown to inhibit NF-B and IRF3-mediated signaling 
through TLRs [104]. 
  Collectively, viral evasion of innate immune responses is 
achieved by expression of viral proteins that inhibit impor-
tant molecules in the signalling cascades triggered by TLRs 
and RNA helicases. 
TLR Agonists in Viral Infections 
  TLRs induce protective immune response against infec-
tions. Novel compounds designed to act as potent agonists 
can be used as therapeutics. The TLR3 agonist poly(I:C) has 
demonstrated antiviral effects in animals [105]. Oligonucleo-
tides that act as TLR9 agonists can lead to cellular activation 
and cytokine production influencing immune response 
against viruses [106]. 
  Recently, the HIV-1 gag protein has been conjugated to 
the TLR7/8 agonist and shown to improve the magnitude 
and quality of T cell responses in non-human primates [107]. 
The TLR7 agonist R-848 can enhance HBsAg-specific hu-
moral and cellular immune responses and together with CpG 
oligonucleotides may be used as adjuvants for therapeutic 
and prophylactic HBV vaccine formulations [108]. nother 
TLR7 agonist, imiquimod, has been successfully used in the 
treatment of HPV [106] and HSV infections [105]. The syn-
thetic imidazoquinoline compounds as TLR8 agonists ex-
hibit immunostimulatory activity [109]. Currently, a number 
of TLR agonists are under investigation and in clinical trials, 
such as the anti-HIV TLR3 agonist poly(I:C12U), the TLR7 
agonist imiquimod, the TLR7/8 agonist resiquimod against 
HSV and HCV, the TLR7 agonist isatoribine, ANA975 and 
the TLR9 agonist CPG10101 against HCV [105]. 
  Extensive knowledge of TLR-dependent viral recognition 
may lead to the generation of new adjuvants and antiviral 
agents. Targeting specific DC subsets with TLR ligands can 
enhance their ability to activate virus-specific T cells, pro-
viding information for the rational design of TLR ligands as 
adjuvants or immuno-modulators [110]. Toll-Like Receptors and Viruses  The Open Microbiology Journal, 2008, Volume 2    55 
Table 1.  TLRs (or RNA Helicases) in Viral Infections and Possible Evasion Mechanisms of TLR-Mediated Antiviral Immunity 
Class* Virus  family  Virus 
Type of nu-
cleic acid 
TLR (or RNA helicases) 
Possible immune evasion 
mechanism 
Herpesviridae  Herpes Simplex Virus 
ds DNA, en-
veloped 
TLR2 [49,50], TLR3 [52], LR7 [53], TLR9 
[54] 
 
 
Varicella Zoster 
Virus 
ds DNA, en-
veloped 
TLR2 [48]   
 Cytomegalovirus 
ds DNA, en-
veloped 
TLR2/CD14 [42], TLR3 [20,45], TLR9 [45]   
 Epstein  Barr  Virus 
ds DNA, en-
veloped 
TLR2 [9], TLR7 [71] 
EBV manipulates TLR7 signal-
ing [71] 
Poxviridae Vaccinia  Virus 
ds DNA, com-
plex coats 
TLR2 [68] 
N1L inhibits NFkB and IRF3 
signaling [104] 
      
A52R and A46R inhibit TIR 
signaling and NFkB activation 
[100,101,103] 
Adenoviridae Adenovirus 
ds DNA, na-
ked 
TLR9 [61,63]   
I 
Papovaviridae Papillomavirus 
ds circular 
DNA, naked 
MyD88 [66], TLR7 [67]   
II Parvoviridae 
Parvovirus (Adeno-
associated) 
ss DNA, naked  TLR9 [112]   
III 
Reoviridae Reovirus 
ds RNA, 
segm., naked 
TLR3 [20], RIG-I, MDA5 [39]   
Picornaviridae  Rhinovirus  ss RNA  TLR3 [22]   
 
Encephalomyocardi-
tis virus 
ss RNA  MDA5 [38]   
  Hepatitis A virus  ss RNA  MDA5 [38] 
3ABC cleavage of MAVS 
[113] 
Flaviviridae Hepatitis  C  virus 
ss RNA, en-
veloped 
TLR2 [80], TLR3 [98], TLR4 [81], TLR7 
[114][77,78], 
NS3/4A cleavage of TRIF [98] 
and MAVS [88] 
      TLR2/1, TLR2/6 [85], RIG-I [99] 
NS5A interacts with MyD88 
and impairs TLR signaling [87] 
  West Nile virus 
ss RNA, en-
veloped 
TLR3 (TNFa) [23]   
 
Japanese encephalitis 
virus 
ss RNA, en-
veloped 
RIG-I [38]   
IV 
 Dengue  virus 
ss RNA, en-
veloped 
RIG-I, MDA5 [39]   
Orthomyxoviri-
dae 
Influenza virus 
ss RNA, segm, 
enveloped 
TLR3 [33], TLR7 [27,29], RIG-1 [35,38,39] 
NS1 protein inhibits function of 
RIG-I [96] 
Paramyxoviri-
dae 
Measles virus 
ss RNA, en-
veloped 
TLR2 [115], TLR4 [95] 
P protein suppresses TLR sig-
naling through upregulation of 
A20 [95] 
 
Respiratory syncytial 
virus 
ss RNA, en-
veloped 
TLR4 [7,36], TLR3 [33], TLR7/MyD88 
[116], RIG-I [39] 
 
V 
  Sendai virus  ss RNA  TLR7/8 [40], RIG-1 [38] 
V protein binds to MDA5 and 
inhibits its activity [94] 56    The Open Microbiology Journal, 2008, Volume 2  Xagorari and Chlichlia 
(Table 1). contd….. 
Class* Virus  family  Virus 
Type of nu-
cleic acid 
TLR (or RNA helicases) 
Possible immune evasion 
mechanism 
  
Newcastle Disease 
virus 
ss RNA  RIG-1 [38]   
 Rhabdoviridae 
Vesicular Stomatitis 
virus 
ss RNA  TLR3 [20], TLR7/MyD88 [29], RIG-1 [38]   
 Arenaviridae 
Lymphocytic 
Choriomeningitis 
Virus LCMV 
ss RNA, 2 
RNAs 
TLR3 [20]   
VI Retroviridae  HIV  ss RNA, en-
veloped 
TLR7/8 [72,73]   
   HTLV  ss RNA, en-
veloped 
MyD88 [74], TLR4 [75]  p30 interferes with TLR4 sig-
naling [75] 
   MMTV  ss RNA, en-
veloped 
TLR4 [76]   
VII  Hepadnaviridae  Hepatitis B virus  ds circular  TLR2 [91,92], TLR3 [93], TLR4, TLR5, 
TLR7 [91] 
 
*according to Baltimore classification of viruses. 
CONCLUSIONS/PERSPECTIVES 
  Members of the TLR family are important pathogen-
recognition receptors and provided a breakthrough in the 
field of microbial pathogenesis and human immunology over 
the recent years. TLRs are present at the cell surface such as 
TLR2 and TLR4, or in endosomal compartments (TLR3, 
TLR7, TLR8). In the cytoplasm RNA helicases represent 
another class of pattern recognition receptors that respond to 
dsRNA. Viral genomes are recognized by different classes of 
TLRs; ssRNA viruses are recognized mainly by TLR7 and 
TLR8, TLR3 responds to dsRNA but also in some cases to 
ssRNA and TLR9 to dsDNA viruses. Consequently, TLRs 
activate signaling pathways leading to the induction of many 
immuno-active cytokines and chemokines. The nucleic acids 
in the viral genomes or envelope glycoproteins or synthetic 
molecules mimicking microbial structures can be detected by 
TLRs triggering antiviral defence mechanisms. Other cyto-
solic receptors, like the cytosolic sensor of dsDNA DAI 
(DLM-1/ZBP1) [111], may also prove to have important 
roles in recognition and antiviral immune responses. 
  While TLR activation triggers antiviral immune de-
fences, excessive TLR activation induced by viruses may 
have detrimental effects for the host. It is necessary to eluci-
date the harmful effects resulting from excessive TLR acti-
vation in viral infections as in the case of West Nile Virus 
[23]. 
  The differential and redundant roles of different TLRs 
and RNA helicases in viral recognition and innate immune 
signaling may reflect unique and shared biological properties 
of certain viruses. The differential triggering of pattern rec-
ognition receptors and control of their gene expression [39] 
as well as their tissue and cell-type specificity may impact 
pathogenesis and infection. 
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ABBREVIATIONS 
AdV =  adenovirus 
BTK =  Bruton’s  tyrosine  kinase 
CARD  =  caspase recruitment domain 
CMV =  cytomegalovirus 
DAI  =  DNA-dependent activator of IFN-regulatory 
factors 
DCs =  dendritic  cells 
ds =  double-stranded 
EBV =  Epstein-Barr  virus 
HCV =  Hepatitis  C  virus 
HIV  =  human immunodeficiency virus 
HSV =  Herpes  simplex  virus 
HTLV  =  Human T cell leukaemia virus 
IFN =  interferon 
IKK =  I-b kinase 
IPS-1  =  interferon-beta promoter stimulator 1 
IRAK  =  IL-1 receptor associated kinase 
IRF  =  interferon regulatory factor 
LCMV  =  Lymphocytic choriomeningitis virus 
Mal =  MyD88-adaptor  like 
MAPK  =  mitogen-activated protein kinase 
MAVS  =  mitochondrial antiviral signalling 
MCMV =  mouse  cytomegalovirus 
MDA5  =  melanoma differentiation-associated gene 5 
mDC =  myeloid  DC 
MMTV  =  mouse mammary tumor virus Toll-Like Receptors and Viruses  The Open Microbiology Journal, 2008, Volume 2    57 
MVA  =  Modified vaccinia virus Ankara 
MyD88  =  myeloid differentiation primary response 
gene 88 
NF-B  =  nuclear factor kappa B 
PAMP =  pathogen-associated  molecular  pattern 
pDC =  plasmacytoid  DC 
RIG-I  =  retinoic acid-inducible gene I 
ss =  single-stranded 
RSV  =  Respiratory syncytial virus 
SeV =  Sendai  virus 
TICAM = Toll-interleukin 1 receptor domain-
containing adaptor molecule 
TIR  =  Toll-interleukin 1 receptor domain 
TIRAP =  TIR-containing  adaptor  protein 
TNF  =  Tumor necrosis factor 
TRAF  =  tumor necrosis factor receptor-associated 
factor 
TRIF  =  TIR-domain containing adaptor inducing 
TNF-beta 
VISA  =  virus-induced signalling adaptor 
VSV  =  vesicular stomatitis virus 
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